206 related articles for article (PubMed ID: 38594285)
21. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract][Full Text] [Related]
22. Validation and comparison of 5th edition World Health Organization classification (WHO 2022) and International Consensus Classification proposals for MDS-SFB31.
Liu L; Li B; Xu Z; Qin T; Jia Y; Qu S; Zhang Y; Wu J; Cai W; Pan L; Gao Q; Jiao M; Xiao Z
Br J Haematol; 2024 Apr; ():. PubMed ID: 38654443
[TBL] [Abstract][Full Text] [Related]
23. The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T.
Kaivers J; Peters J; Rautenberg C; Schroeder T; Kobbe G; Hildebrandt B; Haas R; Germing U; Bennett JM
Leuk Res; 2022 Jan; 112():106757. PubMed ID: 34864369
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
Yin CC; Medeiros LJ; Bueso-Ramos CE
Int J Lab Hematol; 2010 Oct; 32(5):461-76. PubMed ID: 20626469
[TBL] [Abstract][Full Text] [Related]
25. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.
Germing U; Gattermann N; Strupp C; Aivado M; Aul C
Leuk Res; 2000 Dec; 24(12):983-92. PubMed ID: 11077111
[TBL] [Abstract][Full Text] [Related]
26. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
28. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A; Nomdedeu M; Tuechler H; Garcia-Manero G; Komrokji RS; Sekeres MA; Della Porta MG; Cazzola M; DeZern AE; Roboz GJ; Steensma DP; Van de Loosdrecht AA; Schlenk RF; Grau J; Calvo X; Blum S; Pereira A; Valent P; Costa D; Giagounidis A; Xicoy B; Döhner H; Platzbecker U; Pedro C; Lübbert M; Oiartzabal I; Díez-Campelo M; Cedena MT; Machherndl-Spandl S; López-Pavía M; Baldus CD; Martinez-de-Sola M; Stauder R; Merchan B; List A; Ganster C; Schroeder T; Voso MT; Pfeilstöcker M; Sill H; Hildebrandt B; Esteve J; Nomdedeu B; Cobo F; Haas R; Sole F; Germing U; Greenberg PL; Haase D; Sanz G
Leukemia; 2021 Mar; 35(3):835-849. PubMed ID: 32595214
[TBL] [Abstract][Full Text] [Related]
29. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
[TBL] [Abstract][Full Text] [Related]
30. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.
Font P; Loscertales J; Soto C; Ricard P; Novas CM; Martín-Clavero E; López-Rubio M; Garcia-Alonso L; Callejas M; Bermejo A; Benavente C; Ballesteros M; Cedena T; Calbacho M; Urbina R; Villarrubia J; Gil S; Bellón JM; Diez-Martin JL; Villegas A
Ann Hematol; 2015 Apr; 94(4):565-73. PubMed ID: 25387664
[TBL] [Abstract][Full Text] [Related]
31. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.
Falini B; Martelli MP
Am J Hematol; 2023 Mar; 98(3):481-492. PubMed ID: 36606297
[TBL] [Abstract][Full Text] [Related]
33. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
Abdulbaki R; Pullarkat ST
Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
36. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
37. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
38. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
39. [Progress in the diagnosis of and therapy for MDS].
Nannya Y
Rinsho Ketsueki; 2016; 57(10):1980-1990. PubMed ID: 27725596
[TBL] [Abstract][Full Text] [Related]
40. [Myelodysplastic syndromes in adults].
Beyne-Rauzy O; Laurent G; Adoue D
Presse Med; 2007 Mar; 36(3 Pt 2):481-91. PubMed ID: 17336857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
